Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients

Journal of Viral Hepatitis

Volumn 14, Issue 4, 2007, Pages 228-238

  Crespo, M ^a   Sauleda, S ^a   Esteban, J I ^a   Juarez, A ^a   Ribera, E ^a   Andreu, A L ^a   Falco, V ^a   Quer, J ^a   Ocana I ^a   Ruiz, I ^a   Buti, M ^a   Pahissa, A ^a   Esteban, R ^a   Guardia, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Hyperlactataemia and liver failure; Mitochondrial DNA by real time PCR; Mitochondrial toxicity; Treatment of chronic hepatitis C

Indexed keywords

ALPHA2B INTERFERON; ANTIDEPRESSANT AGENT; BICARBONATE; CARNITINE; DIDANOSINE; EFAVIRENZ; GRANULOCYTE COLONY STIMULATING FACTOR; MITOCHONDRIAL DNA; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RIBOFLAVIN; SAQUINAVIR; STAVUDINE; TENOFOVIR; THIAMINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; ASCITES; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DNA CONTENT; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTEROBACTER INFECTION; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HAIR LOSS; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; INFECTION; INSOMNIA; IRRITABILITY; JAUNDICE; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIVER DISEASE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALAISE; MALE; MENTAL DISEASE; MUCOSA INFLAMMATION; MYALGIA; NEUTROPENIA; NEUTROPHIL COUNT; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PNEUMONIA; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SIDE EFFECT; THROMBOCYTE COUNT; TINEA CORPORIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CELL NUCLEUS; DNA; DNA, MITOCHONDRIAL; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN;

EID: 33947366502     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00779.x     Document Type: Article

References (44)

1. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997;35:3274-3277.
2. Esteban JI, Esteban R, Viladomiu L et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989; 2: 294-297.
3. Palella F, Delaney K, Moorman A et al. Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med 1998; 338: 853-860.
4. Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-569.
5. Monga HK, Rodriguez-Barradas MC, Breaux K et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33: 240-247.
6. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-497.7
7. Martinez-Sierra C, Arizcorreta A, Días F et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus an human immunodeficiency virus. Clin Infect Dis 2003; 36: 491-498.
8. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine and efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35: 182-189.
9. Martinez E, Blanco JL, Arnaiz J et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 1261-1268.
10. NIH Consensus Development Conference Statement: management of hepatitis C. Gastroenterology 2002; 123: 2082-2099.
11. Torriani FJ, Rodriguez Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450.
12. Chung RT, Andersen J, Volberding P et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-459.
13. Carrat F, Bani-Sadr F, Pol S et al. Pegylated-interferon-alfa-2b vs interferon-alfa-2b plus ribavirin for chronic hepatitis C in HIV-infected patients. A randomized controlled trial. J Am Med Assoc 2004; 292: 2839-2848.
14. Laguno M, Murillas J, Blanco JL et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18: 0F27.
15. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
16. Fried MW, Shiffman ML, Reddy R et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
17. Hadziyannis SJ, Sette H, Morgan T et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
18. Martell M, Gómez J, Esteban JI et al. High throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J Clin Microbiol 1999; 37: 327-332.
19. Nine JS, Moraca M, Virji MA, Rao KN. Serum-ethanol determination: comparison of lactate and lactic dehydrogenase interference in three enzymatic assays. J Anal Toxicol 1995; 19: 192-196.
20. Vilà MR, Segovia-Silvestre T, Gámez J et al. Long-term survival of a patient with mtDNA depletion syndrome due to TK-2 deficiency. Neurology 2003; 60: 1203-1205.
21. Sauleda S, Esteban JI, Juarez A et al. Preventing lactic acidosis in HIV-HCV coinfected patients during interferon and ribavirin treatment. Development of a real-time PCR for mitochondrial DNA copy number in PBMCs. In: 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 1-5 November 2002. (Abstract 256).
22. Sauleda S, Juarez A, Esteban JI et al. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology 2001; 34: 1035-1040.
23. Côte HCF, Brumme ZL, Craib KJP et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346: 811-820.
24. Vo NV, Young KC, Lai MM. Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry 2003; 42: 10462-10471.
25. Dixit N, Layden-Almer J, Layden T, Perelson A. Modeling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432: 922-924.
26. Núnez M, Camino N, Ramos B et al. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antivir Ther 2005; 10: 657-662.
27. Perez Olmeda M, Nu,nez M, Romero M et al. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17: 1023-1028.
28. Alberti A, Clumeck N, Collins S et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615-624.
29. Soriano V, Nuñez M, Camino N et al. Hepatitis C virus RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antivir Ther 2004; 9: 505-509.
30. Castro FJ, Esteban JI, Juarez A et al. Early detection of non responders to interferon plus ribavirin combination treatment of chronic hepatitis C. J Viral Hepat 2002; 9: 202-207.
31. Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2002; 37: 600-609.
32. Davis G, Wong J, McHutchison J, Manns M, Harvey J, Albrecht J. Early virologic response to treatment with peg-interferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652.
33. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357: 280-281.
34. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silbermann B, Sogni P. Mitochondrial toxicity effects and ribavirin. Lancet 2001; 357: 1803-1804.
35. Moreno A, Quereda C, Moreno L et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther 2004; 9: 133-138.
36. Laguno M, Milinkovic A, de Lazzari E et al. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir Ther 2005; 10: 423-429.
37. Ogedegbe AEO, Thomas DL, Diehl AM. Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis 2003; 3: 329-337.
38. Walker UA, Bäuerle J, Laguno M et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine or zalcitabine. Hepatology 2004; 39: 311-317.
39. Balzarini J, Lee CK, Herdewijn P, de Clercq E. Mechanism of the potentiating effect of ribavirin on the activity of 29, 39-dideoxyinosine against human immunodeficiency virus. J Biol Chem 1991; 266: 21509-21514.
40. Fleisher R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis 2004; 38: e79-e80.
41. Mauss S, Valenti W, DePamphilis J et al. Risk factors for hepatic descompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18: 0F21-F25.
42. Fattovitch G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow up study of 384 patients. Gastroenterology 1997; 112: 463-472.
43. Hu KO, Tong MJ. The long-term outcome of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29: 1311-1316.
44. Lewis J, Huq A, Najarro P. Inhibition of mitochondrial function by interferon. J Biol Chem 1996; 271: 13184-13190.